Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients

Journal of Palliative Medicine

Volumn 16, Issue 8, 2013, Pages 966-970

  Chan, Kwok Ying ^a   Li, Cho Wing ^a   Wong, Hilda ^b   Yip, Terence ^c   Chan, Man Lui ^d   Cheng, Hon Wai ^a   Sham, Mau Kwong ^a  

^a GRANTHAM HOSPITAL   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c TUNG WAH HOSPITAL   (Hong Kong)

^d KOWLOON HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

SERTRALINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; MALE; PALLIATIVE THERAPY; PRURITUS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PALLIATIVE CARE; PRURITUS; RETROSPECTIVE STUDIES; SERTRALINE; TREATMENT OUTCOME;

EID: 84880773097     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2012.0504     Document Type: Article

References (41)

1. Robinson BE: Epidemiology of chronic kidney disease and anemia. J Am Med Dir Assoc 2006;7:(9 suppl)S3-S6.
2. Hamer RA, El Nahas: The burden of chronic kidney disease. BMJ 2006;332:563-564.
3. Dyachenko P, Shustak A, Rozenman D: Hemodialysisrelated pruritus and associated cutaneous manifestations. Int J Dermatol 2006;45:664-667.
4. Dar NR, Akhter A: Clinical characteristics of uremic pruritus in patients undergoing haemodialysis. J Coll Physicians Surg Pak 2006;16:94-96.
5. Pisoni RL, Wikstroin B, Elder SJ, et al.: Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006;21:3495-3505.
6. Duque MI, Thevarajah S, Chan YH, et al.: Uremic pruritus is associated with higher kt/V and serum calcium concentration. Clin Nephrol 2006;66:184-191.
7. Mistik S, Utas S, Ferahbas A, et al.: An epidemiology study of patients with uremic pruritus. J Eur Acad Dermatol Venereol 2006;20:672-678.
8. Patel T, Freedman B, Yosipovitch G: An update on pruritus associated with CKD. Am J Kidney Dis 2007;50:11-20.
9. Mathur VS, Linderg J, Germain M, et al.: A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol 2010;5:1410-9.
10. G Yosipovitch, I Zucker, G Boner, et al.: A questionnaire for the assessment of pruritus: Validation in uremic patients. Acta Derm Venereol 2001;81:108-111.
11. Zucker I, Yosipovitch G, David M, et al.: Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: Uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol 2003;49:842-846.
12. Narita I, Alchi B, Omori K, et al.: Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 2006;69:1626-1632.
13. Mettang T: Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Perit Dial Int 2000;20:802-803.
14. Duque MI, Yosipovitch G, Fleischer AB, et al.: Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: A randomized, double-blind, vehiclecontrolled study. J Am Acad Dermatol 2005;53:519-521.
15. Keithi-reddy SR, Patel TV, Armstrong AW, et al.: Uremic pruritus. Kidney Int 2007; 72:337.
16. Gunal AI, Ozalp G, Yoldas TK, et al.: Gabapentin therapy for pruritus in haemodialysis patients: A randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004;19:3137-3139.
17. Wikström B, Gellert R, Ladefoged SD, et al.: Kappa-opioid system in uremic pruritus: Multicenter, randomized, doubleblind, placebo-controlled clinical studies. J Am Soc Nephrol 2005; 16:3742-3747.
18. To TH, Clark K, Lam L, et al.: The role of ondansetron in the management of cholestatic or uremic pruritus-a systematic review. J Pain Symptom Manage 2012;44:725-730.
19. Zylicz Z, Krajnik M, Sorge AA, Costantini M: Paroxetine in the treatment of severe non-dermatological pruritus: A randomized, controlled trial. J Pain Symptom Manage 2003;26:1105-1112.
20. Ständer S, Bockenholt B, Schü rmeyer-Horst F, et al.: Treatment of chronic pruritus with the selective serotonin reuptake inhibitors paroxetine and fluvoxamine: Results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009; 89:45-51.
21. Biondi M, Arcangeli T, Petrucci RM: Paroxetine in a case of psychogenic pruritus and neurotic excoriations. Psychother Psychosom 2000;69:165-166.
22. Zylicz Z, Smits C, Krajnik M: Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 1998;16:121-124.
23. Tefferi A, Fonseca R: Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002;1;99:26-27.
24. Davis MP, Frandsen JL, Walsh D, et al.: Mirtazapine for Pruritus. J Pain Symptom Manage 2003;25:288-291.
25. U.S. Food and Drug Administration LAB-0540-1.0. Medication guide ZOLOFT (sertraline hydrochloride). http://www .accessdata.fda.gov/drugsatfda-docs/ label/2011/019839/072/075/076, 020990/033/036/037161.pdf
26. Mayo MJ, Handem I, Saldana S, et al.: Sertraline as a firstline treatment for cholestatic pruritus. Hepatology 2007;45: 666-674.
27. Kalivas J, Kalivas L, Gilman D, et al.: Sertraline in the treatment of neurotic excoriations and related disorders. Arch Derm 1996;132:589.
28. Shakiba M, Sanadgol H, Azmoude HR, et al.: Effect of Sertraline on uremic pruritus improvement in ESRD Patients. Int J Nephrol 2012. E-pub 2012 August 29.
29. Greaves MW, Wall PD: Pathophysiology of itching. Lancet 1996;348:938-940.
30. Abbott FV, Hong Y, Blier P: Activation of 5-HT2A receptors potentiates pain produced by inflammatory mediators. Neuropharmacology 1996;35:99-110.
31. Doak GJ, Sawynok J: Formalin-induced nociceptive behavior and edema: Involvement of multiple peripheral 5-hydroxytryptamine receptor subtypes. Neuroscience 1997;80:939-949.
32. Yamaguchi T, Nagasawa T, Satoh M, et al.: Itch-associated response induced by intradermal serotonin through 5-HT2 receptors in mice. Neurosci Res 1999;35:77-83.
33. Cross SA: Pathophysiology of pain. Mayo Clin Proc 1994;69: 375-383.
34. Jett MF, McGuirk J, Waligora D, et al.: The effects of mexilitine, desipramine and fluoxetine in rat models involving central sensitization. Pain 1997;69:161-169.
35. Ardid D, Jourdan D, Mestre C, et al.: Involvement of bulbospinal pathways in the antinociceptive effect of clomipramine in the rat. Brain Res 1995;695:253-256.
36. Muijsers RBR, Plosker GL, et al.: Sertraline: A review of its use in the management of major depressive disorder in elderly patients. Drugs Aging 2002;19:377-392.
37. United Kingdom NHS Lothian Palliative Care Guidelines. Symptom control in patients with chronic kidney disease (national guideline). http://www. palliativecareguidelines .scot.nhs.uk/documents/RenalPalliativeCarefinal.pdf
38. Rayner L, Price A, Hotopf M, et al.: Expert opinion on detecting and treating depression in palliative care: A Delphi study. BMC Palliative Care 2011;10:10.
39. Bernard SA, Bruera E: Drug interactions in palliative care. J Clin Oncol 2000;18:1780-1799.
40. Boyer WF, Feighner JP: Safety and tolerability of selective serotonin re-uptake inhibitors. In: Perspectives in Psychiatry, vol.5 Selective Serotonin Re-uptake Inhibitors, 2nd ed. Chichester: John Wiley and Sons, 1996, pp. 291-314.
41. Seccareccia D, Gebara N: Pruritus in palliative care. Canadian Family Physician 2011;57:1010-1013, e316-e319.